

# Key Figures (IFRS)

MorphoSys Group (in million €, if not stated otherwise)

	12/31/16	12/31/15	12/31/14	12/31/13	12/31/12	12/31/11	12/31/10	12/31/09	12/31/08	12/31/07
<b>RESULTS<sup>1</sup></b>										
Revenues	49.7	106.2	64.0	78.0	51.9	82.1	87.0	81.0	71.6	62.0
Cost of Goods Sold	0.0	0.0	0.0	0.0	0.0	0.0	7.3	6.7	7.1	7.9
R&D Expenses	95.7	78.7	56.0	49.2	37.7	55.9	46.9	39.0	27.6	22.2
SG&A Expenses	14.1	15.1	14.1	18.8	12.1	14.9	23.2	23.9	20.5	24.8
Personnel Expenses (Excluding Stock-Based Compensation)	33.7	32.4	26.7	27.4	24.1	27.7	29.6	26.1	21.5	18.8
Capital Expenditure	2.9	8.8	20.5	5.6	1.8	2.9	13.8	3.8	3.8	12.0
Depreciation of Tangible Assets	1.8	1.5	1.4	1.5	1.7	1.7	2.1	1.6	1.5	1.5
Amortization of Intangible Assets	2.0	1.9	2.7	3.3	3.5	3.8	4.0	3.8	4.8	3.7
EBIT	(59.9)	17.2	(5.9)	9.9	2.5	9.8	13.1	12.8	16.5	8.3
Net Profit/(Loss)	(60.4)	14.9	(3.0)	13.3	1.9	8.2	9.2	9.0	13.2	11.5
Net Profit/(Loss) from Discontinued Operations	-	-	-	6.0	(0.4)	0.0	-	-	-	-
<b>BALANCE SHEET</b>										
Total Assets	463.6	400.1	426.5	447.7	224.3	228.4	209.8	206.1	203.3	184.7
Cash, Marketable Securities and Other Financial Assets	359.5	298.4	352.8	390.7	135.7	134.4	108.4	135.1	137.9	106.9
Intangible Assets	67.9	79.6	46.0	35.1	35.0	66.0	69.2	17.4	19.7	22.3
Total Liabilities	48.1	37.3	77.7	95.5	22.3	31.3	23.9	32.2	41.3	39.2
Stockholders' Equity	415.5	362.7	348.8	352.1	202.0	197.1	185.9	173.9	162.0	145.5
Equity Ratio (in %)	90%	91%	82%	79%	90%	86%	89%	84%	80%	79%
<b>MORPHOSYS SHARE</b>										
Number of Shares Issued	29,159,770	26,537,682	26,456,834	26,220,882	23,358,228	23,112,167	22,890,252	22,660,557	22,478,787	22,160,259
Group Earnings/(Loss) per Share, Diluted (in €)	(2.27)	0.57	(0.12)	0.54	0.08	0.36	0.40	0.40	0.59	0.53
Dividend (in €)	-	-	-	-	-	-	-	-	-	-
Share Price (in €)	48.75	57.65	76.63	55.85	29.30	17.53	18.53	17.04	18.75	16.10
<b>PERSONNEL DATA</b>										
Total Group Employees (Number <sup>2</sup> )	345	365	329	299	421	446	464	404	334	295

<sup>1</sup> Due to the agreement between Bio-Rad and MorphoSys, signed in December 2012, to acquire substantially all of the AbD Serotec segment, for the years 2013, 2012 and 2011, revenues, income and expenses in connection with the transaction are shown in the line item "Net Profit/(Loss) from Discontinued Operations." All other line items consist of amounts from continuing operations.

<sup>2</sup> 2007 to 2012 including employees from the discontinued operations of AbD Serotec.